


Society for Leukocyte Biology



President's Message Bob Clark, President

Excitement continues to build in anticipation of the 49th Annual SLB Meeting in Verona, Italy, September 15 to 17. A joint meeting with "Neutrophil 2016," this promises to

be an outstanding conference in terms of both the exciting science and the spectacular venue. The organizers, Marco Cassatella from SLB and Patrick McDonald from the Neutrophil group, have put together a truly extraordinary agenda. The pace at which meeting registrations are coming in is excellent and we are anticipating strong attendance, including a particularly robust international flavor. Abstract submissions have been very good in both number and quality, as have nominations for travel stipends and named awards. If you have not already reserved your hotel and purchased a plane ticket, I strongly encourage you to do so right away. Hotels are filling up fast for this busy time in Verona. Air fares have been quite favorable recently, but will no doubt be increasing soon. I am very much looking forward to seeing you in Verona!

There has also been a great deal of recent activity in preparation for the 50th Anniversary SLB Meeting in fall 2017. As you will recall, the venue for this meeting was originally to have been Puerto Rico. However, increasing concerns over the spread of Zika virus infections led to reconsideration, especially in the context of Zika transmission in Puerto Rico. Knowledge of this

virus and its transmission via mosquitos has been increasing rapidly, although much remains to be learned. As the SLB executive group debated the issue, we were particularly distressed by the clearly demonstrated Zika-related fetal morbidity and mortality. We felt that the risk engendered by meeting participation in Puerto Rico, especially for our younger members potentially contemplating having children, was simply too great. Therefore, with mixed emotions, we made the decision to identify a new location well outside of the expected range of Zika transmission. Thanks to everyone who has helped the Society work its way through this difficult set of issues. Bill Nauseef was especially insightful in bringing his expertise to bear on the concerns involved. The meeting organizers – Liwu Li and Lionel Ivashkiv – remained remarkably calm throughout all of this, continuing their strong efforts to put together the plans for an outstanding meeting.

Happily, the hard work of Kendra LaDuca and Jennifer Holland has taken us in the direction of Vancouver as the new site for SLB 2017. This should be a great location, as I'm sure that many of you will recall our 2010 Vancouver meeting with much fondness. The plans include an exciting 50th Anniversary Harbor Cruise, again reminiscent of 2010.

Lastly, let me express my thanks to the hard-working members of all SLB committees. I would especially like to recognize the Membership Committee – congratulations on reaching the highest numbers in some years, with the May report showing 823 total members, representing an increase of nearly a third compared with a year ago. Nice going!



Editor's Notes

by Vijaya Iragavarapu-Charyulu and Amanda Brown

Hello everyone! Welcome to the Summer 2016 issue of the iSLB newsletter. The 2016 Joint Annual Meeting of the Society for Leukocyte Biology and Neutrophil Group is only 4 months away! You should already have marked your calendars for this meeting, which takes place in Verona, Italy, a town that looks especially inviting when you think about Romeo and Juliet.

Also, remember that the abstract deadline for this exciting meeting is June 3rd. So I hope that you submitted your abstract! If you haven't submitted an abstract, there is no need to panic. The late-breaking abstract deadline will be open from July 18th through August 1st! Don't forget that with the annual meeting comes the opportunity to apply for the 2016 SLB Awards (leukocytebiology.org/Awards.aspx). I hope that you have applied to them already.



Several features in this issue of i-SLB merit your attention. You will find that our current President, Dr. Robert Clark, highlighted some of the sessions of the joint meeting.

Throughout the year we will continue with the SLB Committee Corner to keep our SLB members up-to-date on the exciting and new endeavors proposed by the different SLB committees. Don't miss reading about the Women and Diversity (W&D) activities and what they have planned for the 2016 meeting. The article on technology driven breakthroughs in leukocyte driven research, submitted by Felix Ellett and Daniel Irimia is very interesting. The Members in Transition and Training Group (MTTG) has enthusiastic members that are actively trying to involve junior scientists in the activities of the Society for Leukocyte Biology. Please take a look at the article on MTTG activities and the interview of Dr. Sudeep Basu written by a member of the MTTG. We expect that this year's annual meeting will be a great one, and so if you have not yet made your reservations for a hotel in Verona, please do so immediately. We would like to thank Cortney Armstrong,

Nominations for Junior Editor for iSLB Newsletter

The Publication Committee is inviting nominations for volunteers to be considered for the next Junior Editor for the iSLB Newsletter. The iSLB Newsletter is published four times each year. This two-year position offers an opportunity for junior scientists (post-doctoral fellows and graduate students) to have their voices heard. The Junior Editor will work with current Junior Editors on the last issue for 2016 and then will take over as a new Junior Editor starting in January of 2017. The Junior Editor works closely with the Editor of iSLB in getting the newsletter ready for publication. If you are interested, please send your CV and a brief statement of why you are interested in this position to Jennifer Holland, Executive Director of SLB (jholland@faseb.org) on or before August 1st, 2016.



Editors Note, continued

one of the Junior Editors who's term is ending at the end of this year, for all the hard work she has done. She and Stephania paved the way for others to get involved by being part of this newsletter. Thanks also to Jennifer Holland in helping with this newsletter. Please take a few moments of your time and enjoy reading this informative newsletter.

We are pleased to announce the call for applications for junior editors for the iSLB newsletter. Courtney and I (Stephania) had a wonderful time highlighting trainees' accomplishments, conducting interviews and writing articles. We encourage everyone who is interested to send their CV and a brief statement describing why you are interested in this position to Jennifer Holland (jholland@faseb.org) by August 1st, 2016.

Junior Editors Note

by Stephania Libreros and Cortney Armstrong



As junior editors, we are excited and grateful for all the opportunities that SLB is providing for a trainee's career development. One of the goals of the SLB is to support trainee's career development by providing opportunities not only financially to attend the annual meeting through travel awards, but by giving the opportunity for trainees to get involved in various types of committees.



These unique opportunities give us the exposure to develop new ideas and to get involved with the matters of the society. There are plenty of opportunities to get involved and participate throughout the year and at the annual meeting. For example, attending this year's MTTG session "Career Beyond the Bench" or the Women and Diversity session "Networking Strategies" allowed for open discussions and networking opportunities between junior scientists and faculty members. Additionally, a "poster flash talks" session was added to the program, which allowed junior society members to participate more fully in the meeting and present their work in front of an audience. Junior members also served as co-chairs for sessions to get first-hand experience in serving as a chair host for various session topics.

If this is your first time attending an SLB annual meeting, there will be numerous occasions to connect with other trainees and start new friendships. Come and join us, submit your abstracts and get involved. We are the future of the society and it is looking bright!

Technology-driven Breakthroughs in Leukocyte Research

by Felix Ellett and Daniel Irimia

The contribution of new technologies to advancing leukocyte biology research is often better appreciated in hindsight. While incremental technological advances directly driven by immediate need or built upon existing techniques are rapidly embraced, larger technological shifts are slower to permeate. The significance of insights enabled by fundamentally new tools can go unrecognized for a long time, until the technologies mature and a major biological breakthrough takes place. Crossing the chasm between emerging technological innovations and advances in leukocyte biology may not always be easy, but it could be very rewarding.

If history is a guide for the future, the pace at which emerging technologies make an impact in leukocyte biology is accelerating. Following the invention of the compound microscope in around 1590 by the Dutch inventors Hans


and Zacharias Janssen, a century passed before the first report of red blood cell morphology by Antoni van Leeuwenhoek in 1695¹. Almost 150 years later, the white blood cells were identified by William Addison in 1843 as the prime cellular constituent of pus², and soon after as an altered blood population in leukaemia³. Further advances in microscope technology, driven largely by the work of Ernst Abbe in Germany⁴, led to the first description of leukocyte motility and host-defence function in starfish by the Russian zoologist Ilya Mechnikov 40 years later in 1882. He extended these findings to identify leukocytes as the primary defence against infection in mammals, and coined the name “phagocytosis” soon after^{5, 6}. Even more details emerged, facilitated by fluorescent proteins such as the jellyfish Green Fluorescent Protein (GFP)⁷ and intravital leukocyte imaging in transparent animal models like *drosophila*⁸ and zebrafish⁹, and in a transgenic mouse model¹⁰. Combined with advances in microscope technology, including lightsheet and two-photon approaches^{11, 12} designed specifically for these models, leukocyte behaviour can now be observed *in vivo* in real-time during response to injury or infection^{13, 14}. This has led to identification of several unexpected cellular behaviours, such as neutrophil reverse migration¹⁵, roles for macrophages in mycobacterial growth and dissemination¹⁶, and identification of “patrolling” neutrophils in microcirculation¹⁷.

In contrast to progress in imaging and molecular techniques, the technologies available for *in vitro* assays of leukocyte behavior have remained largely unchanged for the past fifty years. The first reliable *in vitro/ex vivo* leukocyte migration assay developed by Boyden in 1962¹⁸ is still in use today. This endpoint approach is often complemented by the “bridge” chambers designed by Zygmund in the 1970’s and further improved by Dunn in the 90’s, to visualize chemotaxing cells directly^{19, 20}. However, a technological shift is already taking place beneath the surface. Microfluidics is a technology that has matured for the past two decades largely outside of leukocyte biology and is poised to contribute substantially to the field. Microfluidic approaches are bridging the gap between *in vivo* and *in vitro* assays and *ex vivo* studies of human leukocytes. They provide exceptional control of temporal and spatial conditions, allowing customisation of assay design, specific for the experimental question posed. For example, microfluidic devices have been used to address difficult questions regarding leukocyte chemotaxis upon exposure to complex and dynamic chemoattractant fields²¹⁻²³, coupling of motility and phagocytosis^{24, 25}, and for identifying unexpected migratory behaviours during disease^{26, 27}. Recent studies have highlighted the importance of inflammatory components to the pathology of common

conditions, including cancer, heart disease, sepsis and arthritis²⁸⁻³². In this context, microfluidic approaches can provide rapid bedside assays of innate immune function to predict patient diagnosis and prognosis, and to track disease progression and treatment effectiveness.

Looking to the future, microfluidic technologies are poised to add novel capabilities to the modern leukocyte biologist’s toolbox, providing assays to probe complex and subtle aspects of leukocyte activities in ways that are not possible using current approaches. In recognition of this trend, the Journal of Leukocyte Biology is publishing our review, which encompasses key microfluidic-based studies that have already provided significant insights into leukocyte biology in the context of inflammation and disease. This review is intended to highlight the applicability of various microfluidic approaches to leukocyte biology research, and to provide a practical reference for those researchers seeking customizable experimental tools for *ex vivo* testing of human and animal leukocytes. Early studies demonstrate the potential of these new technologies to expand leukocyte research into new areas, expose unexpected intricacies of health and disease processes, and help reveal the answers to novel questions in leukocyte biology.


For SLB members only, link to microfluidics labs in your area that are interested in collaborating with leukocyte biologists like you!



Microfluidic chip for high precision motility measurements of neutrophils from patients. Courtesy of Daniel Irimia

JLB Accepting Format-Neutral Submissions

JLB is making it more convenient to submit your research for consideration! Starting July 1, 2016 submit your papers in ANY format at first submission (JLB format will be required if a decision to revise is given). Manuscripts do not need to be formatted according to JLB guidelines for an initial submission. The decision of whether to peer review and request a first peer review of a paper will not be affected by formatting. Note, JLB editor will have the option to determine if the format presented impedes a clear evaluation of results and thus return the manuscript to the author to clarify format before a first editorial evaluation can proceed.



Technology Breakthroughs, continued

References

1. Hajdu, S.I., The discovery of blood cells. *Annals of Clinical & Laboratory Science*, 2003. 33(2): p. 237-238.
2. Addison, W., Experimental and practical researches on the structure and function of blood corpuscles; on inflammation; and on the origin and nature of tubercles in the lungs. *Trans. Provinc. Med. Surg. Ass*, 1843. 11: p. 223-306.
3. Bennett, J., Case of hypertrophy of the spleen and liver in which death took place from suppuration. *Edinburgh M. & Surg. J*, 1845. 64: p. 443.
4. Abbe, E., *Neue Apparate zur Bestimmung des Brechungs- und Zerstreungsvermögens fester und flüssiger Körper*. 1874: Mauke's Verlag (Hermann Dufft).
5. Tauber, A.I., Metchnikoff and the phagocytosis theory. *Nat Rev Mol Cell Biol*, 2003. 4(11): p. 897-901.
6. Metchnikoff, E., Sur la lutte des cellules de l'organisme contre l'invasion des microbes. *Ann. Inst. Pasteur*, 1887. 1: p. 321-336.
7. Prasher, D.C., et al., Primary structure of the *Aequorea victoria* green fluorescent protein. *Gene*, 1992. 111(2): p. 229-33.
8. Yeh, E., K. Gustafson, and G.L. Boulianne, Green fluorescent protein as a vital marker and reporter of gene expression in *Drosophila*. *Proc Natl Acad Sci U S A*, 1995. 92(15): p. 7036-40.
9. Amsterdam, A., S. Lin, and N. Hopkins, The *Aequorea victoria* green fluorescent protein can be used as a reporter in live zebrafish embryos. *Dev Biol*, 1995. 171(1): p. 123-9.
10. Ikawa, M., et al., A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP). *FEBS Lett*, 1995. 375(1-2): p. 125-8.
11. Denk, W., J.H. Strickler, and W.W. Webb, Two-photon laser scanning fluorescence microscopy. *Science*, 1990. 248(4951): p. 73-6.
12. Huisken, J., et al., Optical sectioning deep inside live embryos by selective plane illumination microscopy. *Science*, 2004. 305(5686): p. 1007-9.
13. Lammermann, T., et al., Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. *Nature*, 2013. 498(7454): p. 371-5.
14. Luu, L. and J.L. Coombes, Dynamic two-photon imaging of the immune response to *Toxoplasma gondii* infection. *Parasite Immunol*, 2015. 37(3): p. 118-26.
15. Mathias, J.R., et al., Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. *J Leukoc Biol*, 2006. 80(6): p. 1281-8.
16. Davis, J.M. and L. Ramakrishnan, The role of the granuloma in expansion and dissemination of early tuberculous infection. *Cell*, 2009. 136(1): p. 37-49.
17. Phillipson, M. and P. Kubers, The neutrophil in vascular inflammation. *Nat Med*, 2011. 17(11): p. 1381-90.
18. Boyden, S., The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. *J Exp Med*, 1962. 115: p. 453-66.
19. Zigmond, S.H., Ability of polymorphonuclear leukocytes to orient in gradients of chemotactic factors. *J Cell Biol*, 1977. 75(2 Pt 1): p. 606-16.
20. Zicha, D., G.A. Dunn, and A.F. Brown, A new direct-viewing chemotaxis chamber. *J Cell Sci*, 1991. 99 (Pt 4): p. 769-75.
21. Irimia, D., et al., Microfluidic system for measuring neutrophil migratory responses to fast switches of chemical gradients. *Lab Chip*, 2006. 6(2): p. 191-8.
22. Keenan, T.M. and A. Folch, Biomolecular gradients in cell culture systems. *Lab Chip*, 2008. 8(1): p. 34-57.
23. Kim, D. and C.L. Haynes, Neutrophil chemotaxis within a competing gradient of chemoattractants. *Anal Chem*, 2012. 84(14): p. 6070-8.
24. Hamza, B. and D. Irimia, Whole blood human neutrophil trafficking in a microfluidic model of infection and inflammation. *Lab Chip*, 2015. 15(12): p. 2625-33.
25. Chabaud, M., et al., Cell migration and antigen capture are antagonistic processes coupled by myosin II in dendritic cells. *Nat Commun*, 2015. 6: p. 7526.
26. Jones, C.N., et al., Spontaneous neutrophil migration patterns during sepsis after major burns. *PLoS One*, 2014. 9(12): p. e114509.
27. Sackmann, E.K., et al., Characterizing asthma from a drop of blood using neutrophil chemotaxis. *Proc Natl Acad Sci U S A*, 2014. 111(16): p. 5813-8.
28. Meira, L.B., et al., DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J Clin Invest*, 2008. 118(7): p. 2516-25.
29. Coussens, L.M. and Z. Werb, Inflammation and cancer. *Nature*, 2002. 420(6917): p. 860-7.
30. Willerson, J.T. and P.M. Ridker, Inflammation as a cardiovascular risk factor. *Circulation*, 2004. 109(21 Suppl 1): p. II2-10.
31. McInnes, I.B. and G. Schett, The pathogenesis of rheumatoid arthritis. *N Engl J Med*, 2011. 365(23): p. 2205-19.
32. Segel, G.B., M.W. Halterman, and M.A. Lichtman, The paradox of the neutrophil's role in tissue injury. *J Leukoc Biol*, 2011. 89(3): p. 359-72.



The Society of Leukocyte Biology is thrilled to announce the Members in Transition and Training Group (MTTG) will be hosting a session on “Careers Beyond the Bench” during the 2016 annual meeting in Verona, Italy. It is an honor to have Professor Louis Justement from the University of Alabama at Birmingham as one of the panelists. During the session, the speakers will elaborate on different career opportunities for PhDs, including industry and science policy among others. This session will be a great opportunity for graduate student, post-doctoral trainees and early stage industry aspirants, seekers, or explorers to interact in an informal way with the speakers. In addition, each attendee will receive an 8GB flash drive and a raffle ticket for a 3-year SLB membership. Come and join us with all your questions regarding careers either academic or non-academic. For those who are unable to attend the annual meeting, we will write a comprehensive report on the session, and it will be published in the upcoming issue of the iSLB newsletter. One

of the goals of the MTTG is to provide career development activities and supporting materials to foster the professional development of trainees.

We are actively seeking new members who want to be involved within our group, help with the administrative and governing responsibilities of MTTG, and also help organize publications and MTTG related events at annual SLB meetings. If you are a graduate student, post-doctoral fellow, or early stage junior faculty, come participate in our sessions and also share your suggestions for the future of MTTG by following us on our Google Group, LinkedIn and the SLB website.



Photo from the 2015 MTTG Session

Congratulations to Jill Suttles and Charles McCall – 2016 Honorary Member Inductees



Jill Suttles, PhD., has been a member of the SLB for more than 20 years and has served the society in a variety of roles, including as an annual meeting chair, member of the SLB Council, and as President of the SLB for the 2011-2013 term. She also served the Society as a board member and associate editor for the *Journal of Leukocyte Biology*. Dr. Suttles earned her bachelors of science degree in biology at the University of Oregon in Eugene and a doctorate in biology from Brandeis University in Waltham, MA. She completed a post-doctoral fellowship at Wake Forest University Medical Center in Winston-Salem, NC. Following her postdoctoral years, she served as a faculty member and Deputy Chair of the Department of Biochemistry and Molecular Biology at East Tennessee State University. In 1999, she joined the faculty of the Department of Microbiology and Immunology at the University of Louisville School of Medicine. Suttles enjoyed a productive career as a researcher, focusing most of her efforts on macrophage biology. In 2010-11, she was a fellow in the national Executive Leadership in Academic Medicine (ELAM) Program. Her administrative service at U of L included acting as Interim Chair of the Department of Microbiology and Immunology and as Vice Dean for Faculty Affairs and Advancement. Suttles retired from U of L in January of this year and holds the title of Professor Emeritus. She remains dedicated to the field of leukocyte biology, but now spends much of her time gardening, farming, and enjoying music and art.



Charles (Cash) McCall, MD. Professor of Internal Medicine, Translational Science, and Microbiology and Immunology, embarked on his now 50th-year of discovery in leukocyte biology and acute inflammation as an Infectious Diseases Fellow with the late Maxwell Finland, Professor of Medicine, Harvard Medical School, and a founder of the Infectious Diseases Society of America. McCall's first publication on leukocytes in 1969 was based on a patient who died of sepsis. “Lysosomal and Ultrastructural Changes in Human ‘Toxic’ Neutrophils during Infection” was co-authored with his two mentors: Finland and Ramzi Cotran, a pioneer in inflammation research and renowned Mallory Professor of Pathology at Harvard’s Brigham and Women’s Hospital. These two leaders are his academic career heroes, along with Harvard’s renowned hematologist William B. Castle, MD, who discovered “Intrinsic Factor” deficiency in pernicious anemia. Cash received his MD (1961) at Wake Forest Medical School and clinical and research training at the Harvard Medical Services and Thorndike Memorial Laboratory at Boston City Hospital. He has spent his 48-year academic career at Wake Forest, supported by NIH funding for 47 consecutive years. He has mentored many MD and PhD students, post-doctoral trainees, and young faculty. He served as Dean of Research, Interim Chair of Microbiology and Immunology, and Vice-chair for Research in the Department of Internal Medicine. He launched the Sections on Infectious Diseases and Molecular Medicine and was the first Director of the Wake Forest University Translational Science Center.



Careers Choices after PhD

An interview with Sundeep Basu, PhD

In our continuous effort to foster the career development of junior members of SLB, the Members in Transition and Training Group (MTTG) interviewed Sudeep Basu, PhD. After finishing his PhD. in Immunology at the University of Louisville, Dr. Basu began his career as a senior analyst at Frost and Sullivan. Over a short period of 5-7 years, he has successfully carved a niche out for himself, and is currently a Global Practice Leader for Innovation Services at Frost & Sullivan - a consulting firm with a global presence; approximately 2000 people worldwide, and offices in 40+ countries. He is the lead on multiple global initiatives pertaining to driving technology convergence at companies and Universities with an emphasis on innovation; formulating framework for intellectual property policy impacting key countries within an economic group/strata; designing a platform integrating biomarker data with competitive intelligence around future biologics. Apart from what he calls his day job, Dr. Basu is very committed to the training and teaching of trainees and teaches a class at Rutgers and is on advisory committees at the University of Pittsburgh and University of Missouri.

In an interview with MTTG members Juhi Bagaitkar and Hemant Kumar, Dr. Basu shares his experiences, advice and the path he took in pursuing his career after graduate school with the MTTG/SLB members.

Q) How did you choose this career path after getting your PhD. in Immunology?

“I think most careers are at some level an outcome of both, planning and serendipity. My move to consulting from research in graduate school was in general alignment with my long-term goals to address some of the broader and larger challenges that drive scientific developments. While I was reasonably capable and successful in diving deep into one area of research and uncovering answers, I always had this feeling that I needed more. I had a brief stint at my University’s Tech Transfer office spending a few hours a week trying to understand this travelogue of mind to market. That got me hooked to the business world and I requested a professor in the business school who graciously let me sit in on his strategy class. My typical day would begin at 7:00 AM in the tech transfer office, then a full day of graduate research and officially finish up only at 9:00 PM in the business school. Consulting was a natural extension of that interest in business. It was an attempt at trying to make an impact in the realm of business while still being closely in touch with R&D.”

Q) What types of experience is essential?

“The ability to analyze data (scientific, technical, business or policy related) and drawing meaningful conclusions, while simultaneously developing testable hypotheses is critical. Another important soft skill set is to have the personality and confidence to interface with a diverse and vast range of people of varying seniority including company directors, University Presidents, provosts, and on occasion diplomats or political leaders. Experience with articulating ideas and strategies clearly in a convincing manner, while first and foremost listening carefully. This combined with an ability to get a good reading of undertones and personalities (since a lot is left unsaid at times). Lucid yet succinct expression of ideas and opinions and in a professional manner is paramount. Experience in managing people and working with an international team is also crucial.”

Q) What types of employment or internships would you recommend?

“Anything that provides exposure to a global team with a good amount of experience gained in data analysis and summarizing in reports for senior management. One overarching recommendation is gather as many diverse learning experiences as you can through internships,

Baby Announcement!

SLB welcomes our newest and most junior member ever!



HARRY MISHRA

Born May 3, 2016

Length: 21 inches / Weight: 7 lbs

Parents: Hemant and Salesht Mishra

Do you have a new member of your family and wish to share with your SLB community? Send announcements to jholland@faseb.org

volunteering and such, read widely. The beauty of it is that it happens without consciously attempting it. It's like magic!"

Q) What are the typical entry-level opportunities that exist in the field?

"Typical entry-level position in the research and consulting track is an analyst or senior analyst position or a consulting associate depending on the requirements."

Q) Is having a PhD or graduate school education important for someone in this field?

"It is not essential while it can certainly be leveraged as a key differentiator. In my experience, a PhD does provide some pre-assigned credibility to an individual."

Q) How would you describe a typical workweek and a typical day?

"I am a global leader for innovation advisory, so there are really no fixed hours! A typical week may or may not involve domestic or international travel and it is definitely not a 40-hour week. A typical day involves discussions with colleagues and clients across the globe. Review of ongoing projects, proposals, potential opportunities and some administrative work. Once a month the global leadership team is on a call where important initiatives are discussed and selected offices and regions present their ideas and report on progress."

Q) What are the most essential skill sets or talents are most essential for effective job performance?

"Primarily, being passionate about what one does and loving it, finding it exciting is very important. Other than that, multi-tasking, developing an understanding for cultural differences and nuances of business mechanics in each country is essential."

Q) What are some of the toughest problems you must deal with?

"Managing risk and uncertainty is perhaps the toughest problem followed by sticking to a code of ethics while making potentially contentious decisions while being conflicted."

Q) How rapidly is your field expanding?

"The field is not in an exponential growth phase but more in a phase of consolidation. There are trends in big data that

are impacting the business. These trends are to be expected and can actually be a huge advantage to the business if effectively utilized."

Q) What specific aspects of their background should an applicant highlight the most?

"To summarize in 4 points: 1) Ability to travel, across countries and quickly grasp specific issues effectively. 2) A good grasp of knowledge in a few fields and ability to ramp up rapidly to self-learn or gain expertise in newer areas of knowledge. 3) Taking initiative and leadership. 4) Clarity of thought and action."

Q) What type of formal or on-the-job training does the organization provide?

"Several opportunities ranging from tactical HR stuff to strategic skill development, including workshop leadership, thought leadership, presentation skills, team management, and project management."

Q) What is the most rewarding part of your job?

"The fun I have in it because of the people I meet, the friends I gain and the stories I carry while making a small difference somewhere."

Q) How would you describe your work-life balance?

"Work-life balance! What is that? Well, given the nature of global business it can at times be challenging to set the right priorities when there are several demands on one's time and it is a work in progress. Every personal sacrifice must always be weighed and considered very carefully before it is made."

SLB Guest Symposium at AAI 2016



SLB Session at AAI 2016 – Look in the next issue for a detailed summary of this special SLB supported session featuring SLB Awardees.

Coming in the next issue!

2017 Bonazinga Lecturer Announced and more details about the 2017 SLB Anniversary meeting now set for Vancouver, B.C. October 5-7, 2017



A chat with a junior SLB committee member

by Cortney Armstrong and Richard Davis

Rich Davis is a 6th-year graduate student in Immunology at the University of Iowa, defending his dissertation. He studies the interactions between neutrophils and the tropical protozoan parasite *Leishmania* in the laboratory of Dr. Mary Wilson. In 2017, he will be completing a postdoctoral fellowship in clinical microbiology (CPEP program) at ARUP laboratories in Salt Lake City, Utah.

“My invitation to join the SLB Website Committee came about due to a small and innocuous question I was asked in the lobby before the start of the 2014 SLB meeting in Salt Lake City:

“Do you know what hashtag they are using for tweeting this conference?”

It was my first SLB meeting and an outgoing fellow PhD student, Christina Graves, had approached my lab mate Gwen Clay to ask if we would be live-tweeting out the upcoming sessions. The thought of live-tweeting, publishing on the social media platform Twitter short 140 character-messages to summarize the talks from conference speakers, hadn’t even occurred to me. But I gave it a try and found myself liking it so much I live-tweeted out the rest of the conference. During the conference, I was approached by then-chair of the Website Committee, Melanie Scott, and asked about joining this Committee specifically to help run the society’s twitter account (@leukocytebiol).

Being a member of the Website Committee as a junior committee member has been a fantastic opportunity. I have participated in Website committee meetings where we discuss website content and how we can serve the aims of the society. This has provided a behind-the-scenes view of issues including budget constraints, membership outreach, things all professional societies deal with. But my position is more than being a passive participant. Helping to run the Twitter account, I tweet out images and article links from recent JLB publications and live-tweeted the 2015 SLB conference in Raleigh, NC. As a PhD student, being entrusted to represent the society on a social media platform, and being able to contribute ideas and concerns during our quarterly conference calls, I feel like I have a voice in the society and that they value my input.

I am a member of other professional scientific communities other than SLB. But thanks to my participating as a junior committee member, I have been more engaged in this community and feel more excited and committed to continue with it in the future.”



SLB’s Women and Diversity Committee continues to expand their reach!

by Vijaya Iragavarapu-Charyulu and Amanda Brown



The Women and Diversity Committee (W&D) had a wonderful session at the 2015 SLB meeting in Raleigh, North Carolina. Dr. Gail Bishop, the Bonazinga Award winner was the keynote speaker whose topic focused on “Networking” strategies. Her talk was followed by a lively discussion

among the audience and SLB Council members that were present. We would like to thank them for their participation. We’d like to also thank Elizabeth (Liz) Fitzpatrick for a superb job serving as the inaugural chair of the Women & Diversity Committee, which began in 2010. We congratulate her on being elected as a member of the SLB Council and wish her much success in this new position.

We would also like to extend a hearty welcome to three new members to the W&D committee, Dr. Deborah Fraser, a Professor at California State University Long Beach who studies the role of complement proteins in inflammatory diseases like atherosclerosis, Dr. Jessica Snowden, an Associate Professor at University of Nebraska Medical Center studies immune responses within the CNS to a biofilm-mediated foreign body infection, and Dr. Pranoti Mandrekar, a Professor at the University of Massachusetts Medical School who studies innate immune activation in liver diseases and cancer.

HOST A WEBINAR!

SLB is exploring holding webinars year-round outside of the annual meeting. These one hour webinars can be about anything of value to the membership – from a journal article to a technique you are working on.

CONTACT JHOLLAND@FASEB.ORG TO LEARN MORE!

Our Committee is looking forward to active participation from the European community at the 2016 SLB meeting in Vienna. This year's keynote speaker is Dr. Barbara Walzog from Munich, Germany. The topic for this year's Roundtable discussion is "Cultural Differences in the Career Advancement Experience" with the idea of comparing differences between USA and Europe. So, please register to attend the W&D Roundtable discussion as you register for the meeting. We hope to have active participation from both USA and European members.

The Women & Diversity Committee is also sponsoring the 2016 Paper of the Year award to an SLB member who has a paper that has garnered the most citations in the last five years. All SLB members that belong to the "Women and Diversity" category and have published first-author, corresponding-author or a senior-author paper within the last 5 years are invited to apply for this award. The only criterion that will be used for the evaluation of the paper is its impact based on the number of citations per year. The winner will be invited to give a short presentation about his/her research at a session during the Annual SLB Conference. In addition, the awardee will also be invited to participate in the panel discussion during the W&D Forum session and will be featured on the W&D web page. To apply for the W&D "Paper of the Year Award" applicants should use the SLB on-line Award submission system. Submit a statement indicating how you fit the "W&D" category, a short CV and the full reference for one selected article published within the last 5 years with the calculated citations per year according to the Web of Science database. The citation report must also be included with the application. The applicant may be either first author, senior author, or corresponding author. Equal contribution will be given to first, senior and corresponding author. In order to receive this award, the applicant must register and submit an abstract(s) for the

meeting. So, if you think you have a highly cited paper or know an SLB member who has a highly cited paper, please apply/or ask them to apply (see the W&D website).

Do not forget to visit the Women and Diversity committee web page under the Resources Tab on the SLB website.



Professor Charles N. Serhan, SLB member and winner of the 2016 Ross Prize in Molecular Medicine

On June 13, 2016, researchers gathered in New York City for the 2016 Ross Prize in Molecular Medicine: Resolution of Inflammation symposium in honor of 2016 Ross Prize winner Dr. Charles N. Serhan, PhD, DSc, Brigham and Women's Hospital & Harvard Medical School, for his important discoveries in identifying bioactive mediators and cellular pathways critical in the resolution of inflammatory diseases. The Ross Prize recognizes biomedical scientists whose discoveries have changed the way medicine is practiced.

"By using a multidisciplinary approach, Dr. Serhan discovered that inflammation is an active process. His research has led to both a novel understanding of inflammatory pathologies and the subsequent development of therapies for these difficult diseases," says Dr. Kevin J. Tracey, MD, President & Chief Executive Officer, and The Feinstein Institute for Medical Research.

In addition to the presentation of Dr. Serhan's Ross Prize by Dr. Lars Klareskog, MD, PhD, from the Karolinska Institute and Dr. Serhan's keynote lecture, two leading

NEW FOR THE 2016 MEETING!

Due to popular demand, SLB will have a meeting app for 2016. Look for a coming invitation to download the app from Whova and get all the details on your mobile device from program details and full abstracts to networking opportunities to connect directly to other attendees!



Ross Prize winner, continued

researchers presented their work on related emerging approaches for targeting inflammatory diseases, Dr. Mauro Perretti, PhD, from The William Harvey Research Institute, Queen Mary University of London and Dr. Ruslan M. Medzhitov, PhD, from Yale School of Medicine, Howard Hughes Medical Institute.

Professor Serhan says, “I am very pleased and excited to receive this year’s Ross Prize in Molecular Medicine because it honors a new field of research, both our contributions and those of our collaborators. Since many widely occurring diseases are associated with uncontrolled inflammation, such as arthritis, neurodegenerative diseases, and periodontal diseases, the identification of new endogenous pro-resolving mediators and mechanisms are fundamental and now offer many new treatment opportunities for these and other human diseases that involve microbial clearance, organ protection, and tissue regeneration.”

Professor Serhan received a Bachelor of Science in biochemistry from Stony Brook University; followed by a doctorate in Experimental Pathology and Medical Sciences from New York University School of Medicine. From 1981-86, he was a visiting scientist at the Karolinska Institute, Stockholm and post-doctoral fellow with Professor Bengt Samuelsson, 1982 Nobel Laureate. In 1987, he joined the faculty at Harvard and in 1996 he received an honorary degree from Harvard University.

Professor Serhan has received several awards including an NIH MERIT award (2000), the 2008 William Harvey Outstanding Scientist Medal and elected AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology-Bonazinga Award. He recently received the IUBMB award metal in Jan 2016.


For more information about this event visit www.nyas.org/RossPrize2016.

SLB 50th Anniversary Project

SLB is starting to plan for our 50th Anniversary Meeting next year. Have a favorite picture, video, memory from an SLB meeting? Want to share perspectives on how far the science has gone over the last 50 years? **Email videos, audio, text, pictures or anything to jholland@faseb.org to help build the archive of memories!**

ANNOUNCEMENT

**2016
Late Breaking
Abstracts
Opening
July 2016**



Join SLB on LinkedIn – All SLB members are preapproved to join the SLB LinkedIn group.

CLICK HERE TO JOIN TODAY TO GET CONNECTED!



Join the MTTG google group for regular online discussions about topics of interest to trainees.

Email jholland@faseb.org to be invited!